Sugi Predict

Sugi Predict / Compounds / SCHEMBL180224

SCHEMBL180224

SCHEMBL180224

CCC(=O)O[C@]1(C(=O)CO)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ NR3C2 P08235 8/20 1.00
▸ PGR P06401 4/20 0.87
▸ NR3C1 P04150 3/20 0.87
▸ HIF1A Q16665 8/20 0.86
▸ KMT2A Q03164 2/20 0.86
▸ AR P10275 3/20 0.81
▸ CHRM1 P11229 2/20 0.81
▸ SMN1; SMN2 Q16637 3/20 0.70
▸ CYP2C19 P33261 2/20 0.70
▸ HSD17B10 Q99714 2/20 0.70
▸ SERPINA6 P08185 2/20 0.70
▸ MAPT P10636 2/20 0.70
▸ SHBG P04278 1/20 0.70
▸ CYP3A4 P08684 1/20 0.70
▸ NFKB1 P19838 1/20 0.70
▸ LMNA P02545 2/20 0.60
▸ POLB P06746 1/20 0.58
▸ GAA P10253 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14936105 1.00 NR3C2 (1.00) NR3C2PGRNR3C1HIF1AKMT2A
SCHEMBL3050557 1.00 NR3C2 (1.00) NR3C2PGRNR3C1HIF1AKMT2A
SCHEMBL11618795 0.94 NR3C2 (0.88) NR3C2PGRNR3C1HIF1AKMT2A
SCHEMBL11618797 0.94 NR3C2 (0.88) NR3C2PGRNR3C1HIF1AKMT2A
SCHEMBL11751119 0.94 NR3C2 (0.88) NR3C2PGRNR3C1HIF1AKMT2A
Hydrocortisone Butyrate SCHEMBL111478 0.93 NR3C2 (1.00) NR3C2PGRNR3C1HIF1AKMT2A
Hydrocortisone Butyrate SCHEMBL14936050 0.93 NR3C2 (1.00) NR3C2PGRNR3C1HIF1AKMT2A
Hydrocortisone Butyrate SCHEMBL21111521 0.93 NR3C2 (1.00) NR3C2PGRNR3C1HIF1AKMT2A
Hydrocortisone Butyrate SCHEMBL4695 0.93 NR3C2 (1.00) NR3C2PGRNR3C1HIF1AKMT2A
Hydrocortisone Butyrate SCHEMBL14339600 0.93 NR3C2 (1.00) NR3C2PGRNR3C1HIF1AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 247 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250170069-A1 NANOPREPARATION FOR JOINT ANALGESIA, AND PREPARATION METHOD AND USE THEREOF XIANGYA HOSPITAL CENTRAL SOUTH UNIV (CN) 2025-05-29 — — US claimed
EP-4470532-A1 NANO PREPARATION FOR JOINT ANALGESIA, AND PREPARATION METHOD THEREFOR AND USE THEREOF Xiangya Hospital, Central South University (CN) 2024-12-04 — — EP claimed
CN-118662643-A Application of hormone medicine composition in preparation of medicine for treating osteoarthritis 中南大学湘雅医院 2024-09-20 — — CN claimed
CN-118234515-A Methods and therapeutic compositions for treating and preventing severe injection site reactions 腾盛博药生物科技有限公司 2024-06-21 — — CN claimed
CN-118122163-A Low shear mixing method for improving stability of external pharmaceutical preparation composition 江苏知原药业股份有限公司 2024-06-04 — — CN claimed
CN-116098866-A Glucocorticoid fat emulsion for treating arthralgia, preparation method and application thereof 中南大学湘雅医院 2023-05-12 — — CN claimed
CN-116077669-A Glucocorticoid nano-lipid carrier for treating arthralgia, preparation method and application thereof 中南大学湘雅医院 2023-05-09 — — CN claimed
CN-113557020-A Compositions comprising CRAC inhibitors and corticosteroids and methods of use thereof 瑞真药业公司 2021-10-26 — — CN claimed
CN-113332439-A Methods of treatment and compositions comprising dual PI3K delta-gamma kinase inhibitors and corticosteroids 理森制药股份公司 2021-09-03 — — CN claimed
CN-107613985-B Aqueous suspensions of nanoparticles containing glucocorticoids 株式会社活效制药 2021-05-25 — — CN claimed
US-20030077304-A1 Gel composition for the topical treatment of poison ivy and other forms of contact dermatitis MCCADDEN MICHAEL E (US) 2003-04-24 — — US claimed
US-6479058-B1 Composition for the topical treatment of poison ivy and other forms of contact dermatitis MCCADDEN MICHAEL E (US) 2002-11-12 — — US claimed
JP-2002533379-A — — 2002-10-08 — — JP claimed
US-20020064524-A1 Formulation for topical non-invasive application in vivo IDEA AG (DE) 2002-05-30 — — US claimed
EP-1140021-A1 IMPROVED FORMULATION FOR TOPICAL NON-INVASIVE APPLICATION IN VIVO IDEA AG (DE) 2001-10-10 — — EP claimed
WO-2000038653-A1 IMPROVED FORMULATION FOR TOPICAL NON-INVASIVE APPLICATION IN VIVO IDEA AG. (DE) 2000-07-06 — — WO claimed
US-5219877-A Fungicide. antiinflammatory agents BRISTOL-MYERS SQUIBB COMPANY (US) 1993-06-15 — — US claimed
EP-0217141-B1 W/O CREAMS CONTAINING 17-PROPIONATE-21-ACETATE Beiersdorf Aktiengesellschaft (DE) 1990-09-26 — — EP claimed
EP-0217146-B1 W/O CREAMS CONTAINING HYDROCORTISONE DIESTERS Beiersdorf Aktiengesellschaft (DE) 1990-09-12 — — EP claimed
US-4902682-A W/O cream containing hydrocortisone diester BEIERSDORF AG (DE) 1990-02-20 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020064524-A1 Formulation for topical non-invasive application in vivo CUTA, LPO, GPX4 NR3C2 4838/4885PGR 3545/4885NR3C1 4660/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.